Here, we propose the hypothesis that during BCG immunotherapy for bladder cancer, immune activation can lead to a significant amount of FLT3LG secretion, which in turn activates cytotoxic CD8+ T cells within the tumor to exert antitumor activity. This evidence concerns the gene FLT3LG and urinary bladder carcinoma.